SIRT3 as a potential therapeutic target for heart failure

Pharmacol Res. 2021 Mar:165:105432. doi: 10.1016/j.phrs.2021.105432. Epub 2021 Jan 27.

Abstract

Heart failure causes significant morbidity and mortality worldwide. The underlying mechanisms and pathological changes associated with heart failure are exceptionally complex. Despite recent advances in heart failure research, treatment outcomes remain poor. The sirtuin family member sirtuin-3 (SIRT3) is involved in several key biological processes, including ATP production, catabolism, and reactive oxygen species detoxification. In addition to its role in metabolism, SIRT3 regulates cell death and survival and has been implicated in the pathogenesis of cardiovascular diseases. Emerging evidence also shows that SIRT3 can protect cardiomyocytes from hypertrophy, ischemia-reperfusion injury, cardiac fibrosis, and impaired angiogenesis. In this review article, we summarize the recent advances in SIRT3 research and discuss the role of SIRT3 in heart failure. We also discuss the potential use of SIRT3 as a therapeutic target in heart failure.

Keywords: Cardiac remodeling; Heart failure; SIRT3; Sirtuins.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / metabolism*
  • Drug Delivery Systems* / trends
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism*
  • Humans
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Sirtuin 3 / metabolism*

Substances

  • Cardiotonic Agents
  • Reactive Oxygen Species
  • Sirtuin 3